Advertisement
Takeda
Subscribe to Takeda

The Lead

Can Shareholders Stop a Company From Going Global?

June 27, 2014 8:53 am | Videos | Comments

A group of shareholders, led by Yujiro Hara, opposes the hiring of foreign executives at Takeda Pharmaceutical, the biggest drug company in Japan, calling it a “hijacking by foreign capital.”          

MacroGenics and Takeda to Develop DART for Treatment of Autoimmune Disorders

May 27, 2014 9:14 am | News | Comments

MacroGenics and Takeda jointly announced today that they have entered into an option agreement...

Jury Finds for Takeda in Diabetes Drug Case

May 23, 2014 8:07 am | News | Comments

Today's verdict marks the fifth win for Takeda out of six ACTOS (pioglitazone HCL) trials....

FDA Approves Takeda's Entyvio

May 21, 2014 7:59 am | News | Comments

Takeda Pharmaceuticals U.S.A., Inc., today announced that the FDA simultaneously approved a new...

View Sample

FREE Email Newsletter

Court: Misleading Campaign Ad Wasn't Defamatory

May 16, 2014 2:23 pm | by RYAN J. FOLEY, Associated Press | News | Comments

A state senator cannot sue for defamation over a rival's campaign ad that misleadingly suggested he sold dangerous drugs to children, the Iowa Supreme Court ruled Friday in a case that could have implications for politics nationwide.    

Jury Finds for Takeda in Diabetes Drug Case

May 16, 2014 9:22 am | News | Comments

Takeda Pharmaceuticals U.S.A. announced that in the case of Whitlatch v. Takeda the jury found in favor of Takeda. The trial began on April 21 in the Circuit Court of Cook County, Illinois and is the fifth ACTOS (pioglitazone HCl) case to reach trial.

Teva and Takeda to Commercialize Rasagiline for Parkinson’s Disease Treatment in Japan

April 28, 2014 8:18 am | News | Comments

Developed by Teva, rasagiline tablets are approved in over 40 countries for the treatment of Parkinson’s disease. Teva developed this product and received its first approval in 2005 in Israel and Europe, and is currently working towards the acquisition of marketing approval of this product in Japan.

Advertisement

Takeda Names GSK Exec COO

December 2, 2013 8:47 am | News | Comments

Takeda Pharmaceutical has announced that Christophe Weber has been approved at the company's Board of Directors Meeting to become Chief Operating Officer (COO) and candidate as the next Chief Executive Officer (CEO). Mr. Weber will join Takeda to take the role of COO by April 2014.

Takeda and Arbor Announce a Licensing Agreement for EDARBI and EDARBYCLOR

September 13, 2013 8:20 am | News | Comments

Takeda Pharmaceutical Company Limited and Arbor Pharmaceuticals Ireland Ltd., a wholly-owned subsidiary of Arbor Pharmaceuticals, LLC have entered into a license, development and commercialization agreement. It will provide Arbor with exclusive rights to market and sell EDARBI (azilsartan medoxomil) and EDARBYCLOR (azilsartan medoxomil and chlorthalidone) in the U.S. market.

Takeda Launches New Subsidiary in Peru

August 22, 2013 9:34 am | News | Comments

Takeda Pharmaceuticals International GmbH today announced further expansion of its presence in Latin America with the launch of a wholly-owned subsidiary in Peru. Takeda Peru S.R.L. will be headquartered in Lima and will be responsible for the sales and marketing of Takeda's products in Peru.

Sucampo Receives $10M Milestone Payment from Takeda on First Sale of AMITIZA®

June 27, 2013 8:14 am | News | Comments

Sucampo Pharmaceuticals, Inc. (SPI) today announced that it has received a $10 million milestone payment from Takeda Pharmaceutical Company Limited (Takeda), pursuant to the existing collaboration and license agreement between SPI and Takeda. The milestone payment was triggered by the commercial launch of AMITIZA ® (lubiprostone) in the United States for the treatment of opioid-induced constipation (OIC) in adult patient.

Boss Talk Asia: Takeda’s Yasuchika Hasegawa

June 20, 2013 8:39 am | Videos | Comments

Takeda Pharmaceutical Company’s Chief Executive Officer Yasuchika Hasegawa talks to the Wall Street Journal about his management style and “Takeda-ism” – the corporate philosophy that has led Takeda to becomeJapan’s biggest pharmaceutical manufacturer.

Advertisement

Doctor’s Doubts Imperil A Lucrative Diabetes Drug

May 31, 2013 8:05 am | by By ANDREW POLLACK; New York Times News Service | News | Comments

Dr. Peter C. Butler initially declined a request by the drugmaker Merck to test whether its new diabetes drug, Januvia, could help stave off the disease in rats.  “I said, I’m not interested in your money, go away,” Butler recalled. Merck no doubt now wishes it had.

Amag Slumps on Ferahame Recall in Switzerland

May 23, 2013 8:43 am | News | Comments

Amag said its partner Takeda Pharmaceutical is taking a batch of the drug off the market in Switzerland. Amag said four patients experienced severe allergic reactions to the drug, and one of those patients died. That batch was sold only in Switzerland, and the recall doesn't affect any other countries.

Takeda to Acquire Inviragen, Inc.

May 8, 2013 8:04 am | News | Comments

Takeda Pharmaceutical Company Limited and Inviragen, Inc. jointly announced today that Takeda, its wholly owned subsidiary Takeda America Holdings, Inc., and Inviragen, Inc. have entered into a definitive agreement for Takeda to acquire Inviragen for an upfront payment of US$35 million, and future payments of up to US$215 million linked to the progress of clinical development and achievement of key commercial milestones.

Takeda Launches New Subsidiary in Ecuador

March 21, 2013 7:56 am | News | Comments

Takeda Pharmaceuticals International GmbH, today announced further expansion of its presence in Latin America with the launch of its wholly-owned subsidiary in Ecuador. Takeda Ecuador S.A. will be headquartered in Quito and will be responsible for the sales and marketing of Takeda's products in Ecuador.

Biogen Idec, Forest and Bayer Among Top Sponsors Rated by Investigative Sites in New CenterWatch Survey

March 4, 2013 7:59 am | News | Comments

More than 2,000 global investigative sites rate the best biopharmaceutical companies to work for in a new survey conducted by CenterWatch, a provider of global clinical trials information. The survey results were released today in the March issue of The CenterWatch Monthly newsletter.

Advertisement

Takeda and Resolve Therapeutics Enter Autoimmune Partnership

February 28, 2013 7:56 am | News | Comments

Takeda Pharmaceutical Company Limited and Resolve Therapeutics, LLC today jointly announced that they have entered into a partnership to develop compounds for the treatment of lupus (also known as Systemic Lupus Erythematosus, or SLE) and other autoimmune diseases.

Amgen Rises on Recall of Affymax Anemia Drug

February 26, 2013 8:07 am | News | Comments

Shares of Amgen Inc. rose Monday after a drug that competes with Amgen's anemia treatment Aranesp and Epogen was taken off the market because of severe allergic reactions and deaths in some patients. Affymax Inc. and Takeda Pharmaceutical Co. issued a recall of their anemia drug Omontys on Saturday, saying dialysis centers should stop using it.

Affymax and Takeda Announce a Nationwide Voluntary Recall of All Lots of OMONTYS® (peginesatide) Injection

February 25, 2013 7:51 am | News | Comments

Affymax, Inc. and Takeda Pharmaceutical Company Limited (Takeda) have decided to voluntarily recall all lots of OMONTYS® (peginesatide) Injection to the user level as a result of new postmarketing reports regarding serious hypersensitivity reactions, including anaphylaxis, which can be life-threatening or fatal.

Sucampo Files Patent Infringement Lawsuit Against Anchen Pharmaceuticals and Par Pharmaceuticals

February 8, 2013 7:55 am | News | Comments

Sucampo Pharmaceuticals, Inc. today announced that it, its affiliate Sucampo AG, R-Tech Ueno, Ltd., Takeda Pharmaceutical Company Limited (Takeda), and certain affiliates of Takeda have filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Anchen Pharmaceuticals, Inc., Par Pharmaceuticals, Inc. and Par Pharmaceutical Companies, Inc.

Takeda to Acquire Envoy Therapeutics

November 6, 2012 3:31 am | News | Comments

Takeda Pharmaceutical Company Limited (Takeda) and Envoy Therapeutics Inc. (Envoy) jointly announced today that Takeda’s wholly-owned subsidiary, Takeda America Holdings, Inc. and Envoy have entered into a definitive agreement for Takeda America Holdings to acquire Envoy.

Takeda to Acquire LigoCyte Pharmaceuticals

October 5, 2012 4:02 am | News | Comments

Takeda Pharmaceutical Company Limited and LigoCyte Pharmaceuticals, Inc. jointly announced today that Takeda's wholly-owned subsidiary, Takeda America Holdings, Inc. and LigoCyte Pharmaceuticals, Inc. have entered into a definitive agreement for Takeda to acquire LigoCyte for an upfront payment of $60 million, with future contingent consideration based on the progress of development projects.

Takeda Completes its Russian Pharmaceutical Manufacturing Facility

September 11, 2012 3:58 am | News | Comments

Takeda Pharmaceutical International GmbH today announced the completion of construction at its pharmaceutical manufacturing facility in Yaroslavl, Russia.  The Company has invested approximately 75 million in the 24,000m2 production plant, which is expected to be fully operational by 2014.  

Takeda Completes Acquisition of URL Pharma, Inc.

June 4, 2012 4:29 am | News | Comments

Takeda Pharmaceutical Company Limited and its wholly owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., jointly announced that Takeda's wholly owned subsidiary, Takeda America Holdings, Inc., has completed its acquisition of URL Pharma, Inc. for an upfront payment of $800 million.

Canadian Study Suggest Diabetes Drug Increases Risk of Bladder Cancer

June 1, 2012 4:15 am | by Helen Branswell, THE CANADIAN PRESS | News | Comments

TORONTO — A new study adds further weight to the argument that people who use the diabetes drug Actos are at higher risk of developing bladder cancer.  

Takeda to Acquire Multilab, Enhancing its Business Infrastructure in Brazil

May 25, 2012 4:05 am | News | Comments

Takeda Pharmaceutical Company Limited and Multilab Indústria e Comércio de Produtos Farmacêuticos Ltda. today jointly announced that both parties have signed an agreement whereby Takeda Farmacêutica Brasil Ltda., a wholly-owned subsidiary of Takeda, aims to acquire Multilab.  

Takeda Receives Complete Response Letter from the FDA for Type 2 Diabetes Investigational Therapies Alogliptin and Fixed-Dose Combination Alogliptin and Pioglitazone

April 26, 2012 4:28 am | News | Comments

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc. today announced that the company received a complete response letter from the United States (U.S.) Food and Drug Administration (FDA) regarding New Drug Applications (NDAs) for alogliptin and fixed-dose combination (FDC) alogliptin and pioglitazone.

Par Pharmaceutical Acquires Rights to Market and Distribute Generic Dexilant in the U.S.

April 20, 2012 4:11 am | News | Comments

Par Pharmaceutical Companies, Inc. today announced that its Par Pharmaceutical, Inc. operating subsidiary has entered into an exclusive acquisition and license agreement with Handa Pharmaceuticals LLC to acquire Handa's ANDA for dexlansoprazole capsules, the generic version of Takeda's Dexilant.

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading